<DOC>
	<DOCNO>NCT01200017</DOCNO>
	<brief_summary>This protocol provide expanded access bone marrow transplant child lack histocompatible ( tissue match ) stem cell bone marrow donor alternative donor ( unrelated donor half-matched related donor ) available donate . In procedure , blood forming cell ( stem cell ) collect blood partially human leukocyte antigen ( HLA ) match ( haploidentical ) donor transplant patient ( recipient ) administration `` condition regimen '' . A condition regimen consist chemotherapy sometimes radiation entire body ( total body irradiation , TBI ) , meant destroy cancer cell suppress recipient 's immune system allow transplant cell take ( grow ) . A major problem transplant alternative donor increase risk Graft-versus-Host Disease ( GVHD ) , occur donor T cell ( white blood cell involve body 's immune response ) attack tissue organ like skin , liver intestine transplant recipient . In study , stem cell obtain partially-matched donor highly purify use investigational CliniMACS® stem cell selection device effort achieve specific T cell target value . The primary aim study help improve overall survival haploidentical stem cell transplant high risk patient population limit complication GVHD .</brief_summary>
	<brief_title>Expanded Access Protocol ( EAP ) Using CliniMACS® Device Pediatric Haplocompatible Donor Stem Cell Transplant</brief_title>
	<detailed_description>Patients enrol alternative ( mismatched/haplocompatible ) related donor unrelated donor either initial transplant rescue follow rejection previous graft relapse follow previous transplant . For patient mismatch related donor , majority clinical experience T cell-depleted PBSC product . Currently , FDA-approved method T cell depletion exist . Recent experience CliniMACS® device produce excellent result 70-75 % survival child , many high risk patient . Patients receive transplant unrelated donor usually receive stem cell T cell-depleted . However , associate high risk GVHD . The excellent result mismatch related donor transplant justify expand approach unrelated donor transplant recipient HLA mismatch sufficiently great . It anticipate use CliniMACS® device result low risk GVHD without need post-transplant immunosuppression . The outcome relatively small study child receive unrelated donor transplant use CliniMACS® comparable well receive T replete transplant post-transplant immunosuppression . This protocol allow use patient-specific conditioning regimen . Some patient contraindication certain component condition regimen use ongoing study BB-IND 8817 ( CC # 01151 ) . An example patient pre-existing organ dysfunction would better serve use reduce intensity condition regimen . Another example patient total body irradiation contraindicate due young age prior radiation therapy . Finally , patient would otherwise eligible predecessor study eligible relate donor closely match unrelated donor would eligible study . The target CD3+ T cell dose give 3 x 104/kg . The UCSF 01151 protocol us dose 3 x 104/kg . The T cell dose graft usually &lt; 1 x 104/kg processing T cell add product .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Pancytopenia</mesh_term>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<mesh_term>Osteopetrosis</mesh_term>
	<mesh_term>Leukocyte Disorders</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<criteria>Age 0 ( newborn ) 30 year Patient must malignant nonmalignant disease benefit alternative stem cell transplantation accord standard practice guideline . Patients lymphoma acute leukemia ( except acute myeloid leukemia , AML ) must remission time transplant . Patients must lack healthy human leukocyte antigen ( HLA ) identical relate donor . Recipient authorize guardian must sign informed consent study . If recipient female childbearing age , negative pregnancy test . Patient must healthy , willing mismatch relate unrelated donor : Able receive granulocyte colonystimulating factor ( GCSF ) undergo apheresis either placement catheter antecubital vein temporary central venous catheter , For Related donor : sibling , halfsibling , parent , cousin , aunt , uncle grandparent consider eligible . For Related donor : HLA antigen genotypic match ≥ 4/8 ≤ 7/8 ( haplocompatible ) . For unrelated donor : 6/8 7/8 HLA antigen match ( two mismatch , must different locus ) . Complete medical history , physical screen infectious disease acceptable donation . If donor female childbearing age , negative pregnancy test . Absence antiHLA antibody recipient direct donor antigen . Donor must willing sign inform consent study . If donor &lt; 18 year age , donor must willing give assent parent willing sign inform consent . For unrelated donor : The National Marrow Donor Program ( NMDP ) obtain informed consent donor 's apheresis product use study . Age ≥ 5 year Patient anticipate life expectancy &lt; 1 month Active infectious hepatitis cytomegalovirus ( CMV ) disease ( organ involvement ) Human immunodeficiency virus ( HIV ) Human Tlymphotropic virus ( HTLVI/II ) infection Cardiac ejection fraction &lt; 45 % ; low patient clinical cardiac failure reduce intensity condition regimen use . Creatinine clearance &lt; 60 ml/min/1.72 m2 ; low reduce intensity condition regimen use . Pulmonary diffusion capacity ( correct hemoglobin ) , forced expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) &lt; 60 % predict oxygen saturation ( O2 sit ) &gt; 94 % room air unable perform pulmonary function test ( PFTs ) ; low reduce intensity condition regimen use . Serum alanine aminotransferase ( ALT ) &gt; 5 x upper limit normal ( 10x upper limit normal reduce intensity condition regimen use ) bilirubin &gt; 2 . Performance score ( Lansky/Karnofsky ) &lt; 50 Any condition compromise compliance procedure protocol , judge principal investigator .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>T cell deplete</keyword>
	<keyword>Matched unrelated donor</keyword>
	<keyword>Haplocompatible donor</keyword>
	<keyword>Graft v Host Disease</keyword>
	<keyword>Hemoglobinopathies</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Leukemia , Lymphoid</keyword>
	<keyword>Precursor Cell Lymphoblastic Leukemia-Lymphoma</keyword>
	<keyword>Leukemia , Myeloid , Acute</keyword>
	<keyword>Leukemia , Myeloid</keyword>
	<keyword>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Preleukemia</keyword>
	<keyword>Osteopetrosis</keyword>
	<keyword>Pancytopenia</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Genetic Diseases , Inborn</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Lymphatic Diseases</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Myeloproliferative Disorders</keyword>
	<keyword>Bone Marrow Diseases</keyword>
	<keyword>Precancerous Conditions</keyword>
	<keyword>Osteosclerosis</keyword>
	<keyword>Osteochondrodysplasias</keyword>
	<keyword>Bone Diseases , Developmental</keyword>
	<keyword>Bone Diseases</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Severe acquire congenital cytopenia</keyword>
	<keyword>White red blood cell abnormality</keyword>
</DOC>